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Abstract
 
Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and viral pneumonia in
infants and young children. Administration of a formalin inactivated vaccine against RSV to
children in the 1960s resulted in increased morbidity and mortality in vaccine recipients who
subsequently contracted RSV. This incident precluded development of subunit RSV vaccines
for infants for over 30 years, because the mechanism of illness was never clarified. An RSV
vaccine for infants is still not available.
Here, we demonstrate that enhanced RSV disease is mediated by immune complexes and
abrogated in complement component C3 and B cell–deficient mice but not in controls. Fur-
ther, we show correlation with the enhanced disease observed in children by providing evi-
dence of complement activation in postmortem lung sections from children with enhanced
RSV disease.
Key words: respiratory syncytial virus • enhanced disease • immune complexes • airway 
hyperresponsiveness • compliment
 
Introduction
 
Respiratory syncytial virus (RSV) is the leading cause of vi-
ral lower respiratory illness (LRI) in infants and young chil-
 
dren worldwide. Its clinical manifestations range from asymp-
tomatic  infection to LRI with bronchoconstriction and
pneumonia (1). In the 1960s, a formalin inactivated (FI)
RSV vaccine (FIRSV) was administered to infants and
children in the United States. Exposure of vaccinated chil-
dren to RSV resulted in increased frequency and severity of
RSV LRI and greater incidence of hospitalization com-
pared with children immunized with control preparations.
Furthermore, two vaccine recipients died following RSV
infection (2). Investigators hypothesized that immune com-
plexes (ICs) had caused enhanced RSV disease (ERD; ref-
erence 2), but the mechanism of illness was never clarified.
There is still no vaccine licensed against RSV.
A widely accepted hypothesis to explain the pathogene-
sis of ERD has been that disease was caused by an imbal-
ance in the response to RSV attachment (G) and fusion (F)
proteins, because of poor preservation of F during formalin
inactivation (3, 4). The predominance of G in FIRSV is
thought to have led to a pathologic Th2 polarization of the
immune response and pulmonary eosinophilia in immu-
nized individuals infected with RSV. This hypothesis was
supported by a relative excess of eosinophils in the lungs of
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an affected child and high levels of interleukin 4 and pul-
monary eosinophilia in BALB/c mice challenged with
RSV after immunization with either FIRSV, vaccinia virus
encoding G, or purified G protein (2, 4–7). However,
ERD in other mouse strains (8), cotton rats (9), and cattle
(10) is not associated with pulmonary eosinophilia and re-
review of the pulmonary histopathology of affected children
revealed a predominance of neutrophils (11). In addition,
numerous studies have detected an immune response
against F after immunization with FIRSV (12, 13) suggest-
ing that F retains antigenicity after inactivation.
An FI vaccine against measles, another paramyxovirus,
was also developed in the 1960s. The FI measles vaccine
primed for a severe and atypical form of measles character-
ized by fever, a petechial rash and pneumonitis after expo-
sure to WT measles virus. It was recently shown that atypi-
cal measles was associated with IC deposition in affected
tissues, eosinophilia, and a Th2 polarization of the immune
response (14). ICs have been shown to promote Th2 skew-
ing (15). Drawing from similarities between the immune
response associated with ERD and atypical measles, we
sought to test the hypothesis that deposition of IC and
complement activation play an important role in ERD.
 
Materials and Methods
 
Mice.
 
4–6-wk-old female BALB/c (The Jackson Laboratory),
B6129F2 C3
 
 
 
/
 
 
 
, and control mice and C57BL/10 
 
 
 
MT and
control mice (The Jackson Laboratory) housed under laminar
flow hoods in an environmentally controlled specific pathogen-
free animal facility were used for these experiments.
 
Preparation of Vaccines and Immunization.
 
FIRSV was prepared
using the RSV A2 strain grown in Hep-2 cells (2) with and with-
out alum. PIV3 and rRSV
 
 
 
G
 
 (16) were grown in Vero cells. Mice
received the equivalent of 10
 
5
 
 pfu of FIRSV, FIPIV, or FIRSV
 
 
 
G
 
intramuscularly. The dose of FIRSV was selected to allow pul-
monary replication of RSV after challenge. Placebo consisted of
supernatant from lysed uninfected Hep-2 cells in DMEM, 10%
FCS, and 0.4% formalin incubated for 72 h at 37
 
 
 
C and ultracen-
trifuged at 30,000 
 
g
 
 for 30 min. Intranasal immunization used 10
 
5
 
pfu of live RSV A2. 28 d after immunization, all groups were
challenged intranasally with 10
 
6
 
 pfu of RSV A2.
 
Fluorescent Staining.
 
10–20 
 
 
 
m frozen lung sections were
stained for C3 and IgG using a FITC-conjugated Fab goat anti–
mouse C3 (Cappell ICN) and rhodamine-conjugated rabbit anti–
mouse IgG (Pierce Chemical Co.) and isotype control.
 
Airway Hyperresponsiveness.
 
7 d after challenge animals were
anesthetized with sodium pentobarbital (90 mg/kg), intubated,
ventilated at a rate of 120 breaths/min with a constant tidal vol-
ume of air (0.2 ml), and paralyzed with decamethonium bromide
(25 
 
 
 
g/kg). After establishing a stable airway pressure, acetylcho-
line was given intravenously (50 
 
 
 
g/kg) and the dynamic airway
pressure measured for 5 min.
 
Virus Titration in Lung Tissue.
 
Lungs from BALB/c mice were
removed aseptically 4 d after RSV challenge and ground in 3 ml
of HBSS (Bio Whittaker). Debris was pelleted by centrifugation
at 2,000 rpm/5 min and samples plated on Hep-2 cells. Monolay-
ers were overlayed with Opti-MEM (GIBCO BRL) with 2%
FCS, 0.8% methylcellulose, glutamine, and antibiotics, and incu-
bated for 5 d. Plates were stained by the immunoperoxidase
method and results expressed in pfu/g of lung tissue.
 
Antibody Assays.
 
Sera were tested for antibodies to RSV 28 d
after immunization and 7 d after challenge by complement-
enhanced 60% plaque reduction neutralization assay using RSV
A2 and for IgG antibodies to RSV F and G using protein-specific
immunoassays (12).
 
Statistical Analysis.
 
Data were analyzed with statistical soft-
ware (Statview). Comparisons were made using the Mann Whit-
ney U test. All experimentation was approved by and performed
according to guidelines of the Johns Hopkins Medical Institutions.
 
Results
 
ERD Is Associated with Pulmonary IC Deposition and In-
creased Airway Hyperresponsiveness.
 
To determine whether
ERD was associated with pulmonary deposition of IC,
BALB/c mice were immunized with FIRSV and then
challenged with RSV. Mice immunized intramuscularly
with placebo or intranasally with live WT RSV served as
controls (Fig. 1). Lungs of mice immunized with FIRSV
and challenged with RSV stained with hematoxylin and
eosin (H&E) showed a patchy mononuclear cell infiltration
of the alveolar walls and a peribronchiolar and perivascular
lymphomonocytic infiltration with a moderate number of
interspersed neutrophils and eosinophils. Lungs of placebo
recipients and mice immunized with live RSV contained
fewer mononuclear cells after RSV challenge. To examine
the lungs of mice for the presence of IC, frozen lung sec-
tions were stained for IgG and complement component C3
(Fig. 1). Colocalization of IgG and C3 was detected in al-
veolar regions and occasionally in bronchioles of mice with
ERD, but not in lungs of control mice.
Elucidation of the pathogenesis of ERD has been com-
plicated because correlates of RSV disease in the mouse
model have been limited to measures such as weight loss
and the characteristics of the pulmonary cellular infiltrate.
Recently, Peebles et al. demonstrated increased airway hy-
perresponsiveness
 
 (
 
AHR) in mice with ERD compared
with sham immunized mice and mice immunized with live
RSV (17). As bronchoconstriction is a characteristic and se-
rious manifestation of RSV disease and ERD (1, 2), we
measured AHR in the lungs of mice as the primary corre-
late of disease enhancement to compare degrees of illness
elicited by typical and ERD (Fig. 2). After RSV challenge,
mice immunized with FIRSV developed ERD with a sig-
nificant increase in AHR compared with placebo recipients
(P
 
 
 
  
 
0.001), mice immunized with a control FI parainflu-
enza virus type 3 vaccine (FIPIV; P 
 
  
 
0.002), and mice
immunized intranasally with live RSV (P
 
 
 
  
 
0.001). The
difference between groups was conserved when inactivated
vaccines were administered with alum and reproduced in
B6129F2 mice (unpublished data).
 
RSV G Glycoprotein Is Not Required to Prime for ERD.
 
To determine whether ERD was associated with an ab-
normal immune response against G in FIRSV, we immu-
nized BALB/c mice with a FI, recombinant RSV that
does not express G (rRSV
 
 
 
G
 
; reference 16). Cellular infil-
tration in lung biopsies, IC deposition, and AHR after
challenge were similar in FIRSV
 
 
 
G
 
 and FIRSV recipients 
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(Figs. 1 and 2) demonstrating that G is not necessary to
prime for ERD.
 
A Role for Antibody and Complement in ERD.
 
To assess
the role of complement in ERD we immunized C3 defi-
cient (C3
 
 
 
/
 
 
 
) and WT mice with FIRSV and challenged
them with RSV. Both groups developed similar alveolar,
peribronchiolar, and perivascular mononuclear cellular in-
filtration with many interspersed neutrophils (Fig. 3). Fro-
zen sections confirmed deposition of C3 and IgG in alveoli
and scattered bronchioles of WT mice, but only IgG was
present in lungs of C3
 
 
 
/
 
 
 
 mice (unpublished data). Al-
though the histopathology in C3
 
 
 
/
 
 
 
 and WT mice was
similar, pulmonary function studies revealed clear differ-
ences between the two groups. FIRSV-immunized, RSV-
challenged WT mice had a significant increase in AHR
compared with C3
 
 
 
/
 
 
 
mice (P
 
 
 
 
 
 
 
0.001), demonstrating
that complement is critical for bronchoconstriction in
ERD (Fig. 4 A). AHR was not different in naive C3
 
 
 
/
 
 
 
and WT mice (unpublished data).
Figure 1. Pulmonary histopathology 7 d after RSV challenge in mice that had received the indicated preimmunization (10 ). Hematoxylin and eosin
(A); immunofluorescence staining for C3 (FITC; B), IgG (rhodamine; C) and colocalization of C3 and IgG (D).
 
Figure 2.
 
AHR 7 d after RSV challenge in previously immunized
BALB/c mice. AHR to acetylcholine challenge is defined by the time-
integrated rise in peak airway pressure. Results are means 
 
 
 
 SEM (error
bars) of 7–10 animals per group and are representative of two indepen-
dent experiments. 
 
*
 
P
 
 
 
  
 
0.05 compared with placebo, RSV, and FIPIV.
 
**
 
P
 
 
 
  
 
0.05 compared with placebo, RSV, and FIPIV. 
 
*
 
 vs. 
 
**
 
: P 
 
  
 
0.29. 
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To further explore the role of IC in ERD, B cell–defi-
cient (B
 
 
 
/
 
 
 
), and WT mice were immunized with FIRSV
and challenged with RSV. As observed with C3
 
 
 
/
 
 
 
 mice,
B
 
 
 
/
 
  
 
and WT mice developed similar pulmonary inflam-
matory infiltrates (unpublished data). However, WT mice
challenged with RSV had a significant increase in bron-
choconstriction compared with B
 
 
 
/
 
 
 
 mice (P
 
 
 
  
 
0.009;
Fig. 4 B). This confirmed the role of antibodies in ERD
and provided additional evidence that pneumonia and
bronchoconstriction are distinct phenomena.
 
Nonprotective Antibody Response to RSV in Mice Primed
with FIRSV.
 
To determine whether ERD is associated
with higher titers of RSV in the lungs of affected mice than
in control groups, we compared viral titers after RSV chal-
lenge in mice previously immunized with FIRSV, placebo,
or live RSV. RSV titers were similar in mice with ERD
and placebo recipients infected with RSV, but undetect-
able in mice protected by prior intranasal infection with
live RSV (Table I). These differences could not be ex-
plained by differences in serum glycoprotein-specific IgG
levels (Table I). Serum anti-G and anti-F IgG levels were
high after vaccination and challenge in FIRSV and live
RSV groups (P
 
 
 
  
 
0.71 for G and P 
 
 
 
 0.44 for F after chal-
lenge). However, mice with ERD had no detectable neu-
tralizing antibodies after vaccination or challenge, whereas
mice primed with WT RSV had high levels of neutralizing
antibodies after vaccination and were protected against
challenge. As expected, placebo recipients infected with
RSV had lower levels of anti-G and anti-F IgG than either
of the previously primed groups.
7 d after RSV challenge, anti-F and anti-G IgM were
detectable in naive and FIRSV-immunized mice but not in
mice protected by live RSV. Levels of anti-F and -G IgA
were similar in all groups. Determination of IgG subclasses
in FIRSV and RSV recipients demonstrated that anti-
body to F was predominantly complement-fixing IgG2a,
whereas antibody to the heavily-glycosylated protein G was
predominantly IgG2b. However, there were no clear dif-
ferences in IgG subclass responses between the groups (un-
published data).
 
Evidence for Activation of the Classic Complement Cascade in
Lung Sections of Children with ERD.
 
To confirm the role
of complement in the pathophysiology of ERD we used an
antibody against C4d to stain lung sections of the two chil-
dren who died of ERD (18). The complement cleavage
product C4d is a sensitive marker of complement activation
mediated by IC using the classical pathway, and can be de-
tected in biopsies obtained years earlier (18). Lung sections
Figure 3. Hematoxylin and eosin stained pulmonary sections of C3 ET ( / ) and deficient ( / ) mice preimmunized with FIRSV and challenged
with RSV.
Figure 4. AHR 7 d after RSV challenge previously immunized with
FIRSV. (A) B6129F2 WT (C3 / ) and C3 deficient (C3 / ),*: P   
0.001; and (B) C57BL/10 (B / ) and B10  MT (B / ) mice, **: P  
0.009. AHR to acetylcholine challenge is defined by the time-integrated
rise in peak airway pressure. Results are means   SEM (error bars) of 9–12
animals per group and are representative of three independent experiments. 
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of both children had extensive peribronchiolar deposition
of C4d (Fig. 5). No evidence of nonspecific binding of the
C4d antibody was observed in sections of two control pa-
tients with nonhematologic malignancies (representative
example shown in Fig. 5). These controls were used to
show the binding specificity of the anti-C4d antibodies, as
lung biopsy material from a normal infant with nonfatal
RSV infection, paralleling the experimental and control
samples from mice shown in Fig. 1, was unavailable.
 
Discussion
 
This study demonstrates that IC that fix complement are
important in the pathogenesis of ERD. Antibody deposi-
tion in FIRSV-immunized mice does not result in ERD
after RSV challenge in the absence of complement activa-
tion and complement cannot elicit ERD in the absence of
antibodies. Peribronchiolar C4d deposition in children
with ERD provides conclusive evidence of antibody-medi-
ated activation of the classic complement cascade during
this process. Moreover, the quality of antibody elicited also
appears to be important. IC formation is associated with
the presence of large amounts of nonneutralizing antibody
at the time of pulmonary RSV replication; large amounts
of neutralizing antibody elicited by prior WT infection
protect against challenge with RSV and do not lead to
ERD, as demonstrated in infants at increased risk of severe
RSV disease (19).
These high levels of nonneutralizing antibody suggest
that formalin disrupts critical epitopes during the process of
inactivation (12, 13). Alternatively, an altered maturation
of the B cell response after FIRSV may account for the
abundant, nonprotective antibody response leading to IC
deposition. Low avidity antibodies have been associated
with IC-mediated disease and may explain IC deposition
during ERD (20). Data from atypical measles show that B
 
Table I.
 
RSV Antibody and Viral Titers in Preimmunized Mice
 
After immunization After challenge
RSV titer
(log pfu/g) Vaccine PRNT EIA F EIA G PRNT EIA F EIA G
FIRSV
 
 
 
10 658 
 
  22 139   12  10 885   18 292   16 3.96   0.01
Placebo  10  50  50  10 170   24 68   4 3.98   0.02
RSV IN 164   3 833   12 148   8 205   7 971   10 261   8  0.6
Antibody responses in BALB/c mice determined 28 d after immunization and 7 d after RSV challenge and RSV pulmonary titers 4 d after challenge.
PRNT, RSV-specific neutralization as measured by 60% complement-enhanced plaque reduction; EIA-F, immunoassay determination of IgG
antibodies against RSV F protein (change in absorbance); EIA G, immunoassay determination of IgG antibodies against RSV G protein (change in
absorbance). Results are means   SEM of 8–10 animals per group.
Figure 5. Deposition of C4d in pulmonary tissue of both patients (1 and 2) who died of ERD in 1967 and control patient (control). Immunohis-
tochemistry staining for C4d (A) and preimmune rabbit sera (B) (reference 18).864 Immune Complexes Causing Enhanced Respiratory Syncytial Virus Disease
cells of macaques primed with FI measles fail to undergo
affinity maturation and display high levels of low avidity,
nonprotective antibody when infected with measles (un-
published data). It is likely that ERD and atypical measles
have strong parallels. Either process, formalin-mediated
disruption of neutralizing epitopes or lack of affinity matu-
ration, could result in the presence of abundant nonpro-
tective RSV-binding antibodies in the face of extensive
RSV antigen production and provide the basis for IC for-
mation in the infected airways. This strong nonneutraliz-
ing antibody response may be stimulated by the Th2
polarization observed in recipients of FIRSV, an RSV-
vaccine that does not elicit Th-modulatory cytotoxic T
lymphocyte responses (21, 22). IC themselves may also en-
hance antibody production and promote a Th2 bias of the
immune response (15).
In our study, complement and antibody deficient and
WT mice had similar pulmonary inflammatory infiltration,
but significantly different airway responses. This suggests
that AHR in this mouse model is not associated with the
degree of pneumonia, although it may be promoted by cel-
lular degranulation or release of other inflammatory media-
tors associated with complement activation. A similar disso-
ciation between AHR and pulmonary inflammatory cells
has been reported in other murine models of allergic
asthma (23). In the past, passive transfer of sera from
FIRSV-immunized mice failed to elicit an “enhanced”
pneumonia in naive mice upon RSV challenge (broncho-
constriction was not measured). This may be explained by
the lack of primed T helper lymphocytes recruiting inflam-
matory cells to the lungs at the time of challenge (24) and is
in agreement with our observation that factors other than
complement attract inflammatory cells to the lung during
ERD (12, 13).
We do not exclude a role for cellular infiltrate in ERD, a
phenomenon that is likely complex and multifactorial. The
pneumonia has been shown to be a T cell–dependent man-
ifestation of ERD (4, 24) and the inflammatory infiltrate (2,
11) may play a functional role in other manifestations. The
regulatory role of T helper cells in AHR and whether
granulocytes can directly cause bronchoconstriction should
be further investigated. However, none of these clinical
signs appear to require priming by the G glycoprotein.
The complement system may injure tissue through for-
mation of the cell-lytic complex C5b-9, or by action of
complement anaphylotoxins (C3a, C4a, and C5a) elicit
bronchoconstriction, mucus secretion, or recruit inflamma-
tory cells promoting degranulation and disease. Comple-
ment factors can also promote T cell activation (a feature of
both ERD and atypical measles [25, 26]) and affect the lev-
els of proinflammatory cytokines. Recent papers have de-
scribed a role for the C3a anaphylotoxin in the effector
phase of allergic bronchoconstriction (27), a modulatory
role for C5 in allergic asthma (28), and a critical role for
C5a in IC-mediated alveolitis (29). ERD was characterized
by bronchoconstriction and pneumonia (2), both signs that
may be associated with anaphylotoxin activity (27–30).
Preliminary studies in our laboratory demonstrate high
AHR in A/J mice with ERD. As A/J mice are deficient in
functional C5, these data would support an effector role for
C3a in bronchoconstriction.
This study provides a new model for ERD that can be
used to screen future candidate vaccines. This model is re-
producible in multiple strains of mice, detects ERD by a
correlate (bronchoconstriction) that is directly relevant to
clinical RSV disease in humans, provides quantitative viro-
logic data and pulmonary histopathology, and differs from
another model that measured AHR in that concomitant al-
lergic sensitization is not required (17).
In summary, bronchoconstriction in ERD is mediated
by IC and can be elicited by immunization with FIRSV in
the absence of the G glycoprotein. Whether this pathologic
response is specific to FI vaccines remains to be deter-
mined. Therefore, extreme caution should be exercised in
the evaluation of nonreplicating RSV vaccines in infants.
We thank Bhagvanji Thumar, Liliana Moreno, and Jean Froehlich
for expert assistance, Dr. Diane E. Griffin and Dr. Robert M. Cha-
nock for helpful discussions, and Dr. Roma Chandra for access to
the human autopsy material and data.
This study was supported in part by The Thomas and Carol Mc-
Cann Innovative Research Fund for Asthma and Respiratory Dis-
ease (FPP).
Submitted: 14 May 2002
Revised: 24 July 2002
Accepted: 12 August 2002
References
1. Collins, P.L., R.M. Chanock, and B.R. Murphy. 2001.
Fields Virology. D.M. Knipe and P.M. Howley, editors. Lip-
pincott Williams and Wilkins, Philadelphia, PA. 1443–1486.
2. Kim, H.W., J.G. Canchola, C.D. Brandt, G. Pyles, R.M.
Chanock, K. Jensen, and R.H. Parrott. 1969. Respiratory
syncytial virus disease in infants despite prior administration
of antigenic inactivated vaccine. Am. J. Epidemiol. 89:422–
434.
3. Graham, B.S. 1995. Pathogenesis of respiratory syncytial vi-
rus vaccine-augmented pathology. Am. J. Respir. Crit. Care
Med. 152:S63–S66.
4. Connors, M., N.A. Giese, A.B. Kulkarni, C.Y. Firestone,
H.C. Morse III, and B.R. Murphy. 1994. Enhanced pulmo-
nary histopathology induced by respiratory syncytial virus
(RSV) challenge of FI RSV-immunized BALB/c mice is ab-
rogated by depletion of interleukin-4 (IL-4) and IL-10. J. Vi-
rol. 68:5321–5325.
5. Graham, B.S., G.S. Henderson, Y.W. Tang, X. Lu, K.M.
Neuzil, and D.G. Colley. 1993. Priming immunization de-
termines T helper cytokine mRNA expression patterns in
lungs of mice challenged with respiratory syncytial virus. J.
Immunol. 151:2032–2040.
6. Hancock, G.E., D.J. Speelman, K. Heers, E. Bortell, J.
Smith, and C. Cosco. 1996. Generation of atypical pulmo-
nary inflammatory responses in BALB/c mice after immuni-
zation with the native attachment (G) glycoprotein of respi-
ratory syncytial virus. J. Virol. 70:7783–7791.
7. Openshaw, P.J., S.L. Clarke, and F.M. Record. 1992. Pul-
monary eosinophilic response to respiratory syncytial virus
infection in mice sensitized to the major surface glycoprotein865 Polack et al. Brief Definitive Report
G. Int. Immunol. 4:493–498.
8. Hussell, T., A. Georgiou, T.E. Sparer, S. Matthews, P. Pala,
P.J. Openshaw. 1998. Host genetic determinants of vaccine-
induced eosinophilia during respiratory syncytial virus infec-
tion. J. Immunol. 161:6215–6222.
9. Prince, G.A., A.B. Jenson, V.G. Hemming, B.R. Murphy,
E.E. Walsh, R.L. Horswood, and R.M. Chanock. 1986. En-
hancement of respiratory syncytial virus pulmonary pathol-
ogy in cotton rats by prior intramuscular inoculation of FI vi-
rus. J. Virol. 57:721–728.
10. Gershwin, L.J., E.S. Schelegle, R.A. Gunther, M.L. Ander-
son, A.R. Woolums, D.R. Larochelle, G.A. Boyle, K.E.
Friebertshauser, and R.S. Singer. 1998. A bovine model of
vaccine enhanced respiratory syncytial virus pathophysiology.
Vaccine. 16:1225–1236.
11. Prince, G.A., S.J. Curtis, K.C. Yim, and D.D. Porter. 2001.
Vaccine-enhanced respiratory syncytial virus disease in cotton
rats following immunization with Lot 100 or a newly pre-
pared reference vaccine. J. Gen. Virol. 82:2881–2888.
12. Murphy, B.R., A. Sotnikov, P.R. Paradiso, S.W. Hildreth,
A.B. Jenson, R.B. Baggs, L. Lawrence, J.J. Zubak, R.M.
Chanock, J.A. Beeler, et al. 1989. Immunization of cotton
rats with the fusion (F) and large (G) glycoproteins of respira-
tory syncytial virus (RSV) protects against RSV challenge
without potentiating RSV disease. Vaccine. 7:533–540.
13. Connors, M., P.L. Collins, C.Y. Firestone, A.V. Sotnikov,
A. Waitze, A.R. Davis, P.P. Hung, R.M. Chanock, and
B.R. Murphy. 1992. Cotton rats previously immunized with
a chimeric RSV FG glycoprotein develop enhanced pulmo-
nary pathology when infected with RSV, a phenomenon not
encountered following immunization with vaccinia-RSV re-
combinants or RSV. Vaccine. 10:475–484.
14. Polack, F.P., P.G. Auwaerter, S.H. Lee, H.C. Nousari, A.
Valsamakis, K.M. Leiferman, A. Diwan, R.J. Adams, and
D.E. Griffin. 1999. Production of atypical measles in rhesus
macaques: evidence for disease mediated by IC formation and
eosinophils in the presence of fusion-inhibiting antibodies.
Nat. Med. 5:629–634.
15. Anderson, C.F., and D.M. Mosser. 2002. Cutting edge: bias-
ing immune responses by directing antigen to macrophage fc-
gamma receptors. J. Immunol. 168:3697–3701.
16. Teng, M.N., S.S. Whitehead, and P.L. Collins. 2001. Con-
tribution of the respiratory syncytial virus G glycoprotein and
its secreted and membrane-bound forms to virus replication
in vitro and in vivo. Virology. 289:283–296.
17. Peebles, R.S., Jr., J.R. Sheller, R.D. Collins, K. Jarzecka,
D.B. Mitchell, and B.S. Graham. 2000. Respiratory syncytial
virus (RSV)-induced AHR in allergically sensitized mice is
inhibited by live RSV and exacerbated by FI RSV. J. Infect.
Dis. 182:671–677.
18. Regele, H., M. Exner, B. Watschinger, C. Wenter, M.
Wahrmann, C. Osterreicher, M.D. Saemann, N. Mersich,
W.H. Horl, G.J. Zlabinger, G.A. Bohmig. 2001. Endothelial
C4d deposition is associated with inferior kidney allograft
outcome independently of cellular rejection. Nephrol. Dial.
Transplant. 16:2058–2066.
19. Groothuis, J.R., E.A. Simoes, M.J. Levin, C.B. Hall, C.E.
Long, W.J. Rodriguez, J. Arrobio, H.C. Meissner, D.R. Ful-
ton, R.C. Welliver, et al. 1993. Prophylactic administration
of respiratory syncytial virus immune globulin to high-risk
infants and young children. The Respiratory Syncytial Virus
Immune Globulin Study Group. N. Engl. J. Med. 329:1524–
1530.
20. Devey, M.E., and M.W. Steward. 1980. The induction of
chronic antigen-antibody complex disease in selectively bred
mice producing either high or low affinity antibody to pro-
tein antigens. Immunology. 41:303–311.
21. Srikiatkhachorn, A., T. Braiciale. 1997. Virus-specific CD8 
T lymphocytes downregulate T helper cell type 2 cytokine
secretion and pulmonary eosinophilia during experimental
murine respiratory syncytial virus infection. J. Exp. Med. 186:
421–432.
22. Hussell, T., C.J. Baldwin, A. O’Garra, and P.J. Openshaw.
1997. CD8  T cells control Th2-driven pathology during
pulmonary respiratory syncytial virus infection. Eur. J. Immu-
nol. 27:3341–3349.
23. Wills-Karp, M., J. Luyimbazi, X. Xu, B. Schofield, T.Y.
Neben, C.L. Karp, and D.D. Donaldson. 1998. Interleukin-
13: central mediator of allergic asthma. Science. 282:2258–
2261.
24. Connors, M., A.B. Kulkarni, C.Y. Firestone, K.L. Holmes,
H.C. Morse III, A.V. Sotnikov, and B.R. Murphy. 1992.
Pulmonary histopathology induced by respiratory syncytial
virus (RSV) challenge of FI RSV-immunized BALB/c mice
is abrogated by depletion of CD4  T cells. J. Virol. 66:7444–
7451.
25. Kim, H.W., S.L. Leikin, J. Arrobio, C.D. Brandt, R.M.
Chanock, and R.H. Parrott. 1976. Cell-mediated immunity
to respiratory syncytial virus induced by inactivated vaccine
or by infection. Pediatr. Res. 10:75–78.
26. Kraus, P.J., J.D. Cherry, J.M. Carney, M.J. Naiditch, and K.
O’Connor. 1980. Measles-specific lymphocyte reactivity and
serum antibody in subjects with different measles histories.
Am. J. Dis. Child. 134:567–571.
27. Humbles, A.A., B. Lu, C.A. Nilsson, C. Lilly, E. Israel, Y.
Fujiwara, N.P. Gerard, and C. Gerard. 2000. A role for the
C3a anaphylatoxin receptor in the effector phase of asthma.
Nature. 406:998–1001.
28. Karp, C.L., A. Grupe, E. Schadt, S.L. Ewart, M. Keane-
Moore, P.J. Cuomo, J. Kohl, L. Wahl, D. Kuperman, S.
Germer, et al. 2000. Identification of complement factor 5 as
a susceptibility locus for experimental allergic asthma. Nat.
Immunol. 1:221–226.
29. Hopken, U.E., B. Lu, N.P. Gerard, and C. Gerard. 1997.
Impaired inflammatory responses in the reverse arthus reac-
tion through genetic deletion of the C5a receptor. J. Exp.
Med. 186:749–756.
30. Zhang, Y., B.F. Ramos, and B.A. Jakschik. 1992. Neutrophil
recruitment by tumor necrosis factor from mast cells in IC
peritonitis. Science. 258:1957–1959.